Study of BL-M07D1 and Pembrolizumab for HER2+ Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug combination, BL-M07D1 plus pembrolizumab (an immunotherapy), for people with a certain type of advanced lung cancer that has high levels of HER2 protein. The goal is to see if the combination is safe and effective for people who have not been treated with HER2-targeting drugs before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC) that is advanced or has spread
- Your tumor must have high levels of HER2 protein (tested by a biopsy)
- You should be between 18 and 75 years old
- You must be willing to provide a sample of your old tumor tissue (from the past 2 years)
- You should not have had certain cancer treatments (like surgery, radiation, or immunotherapy) in the 4 weeks before starting
- You must not have untreated or active brain metastases, or a history of interstitial lung disease requiring steroids
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
This trial tests a new drug combination for people with a type of lung cancer that has spread or cannot be removed by surgery. It compares the new combination to the current standard treatment to see which works better.
This trial tests a new drug called BL-M07D1 for women with HER2-positive or low-HER2 gynecologic cancers that have returned or spread. The drug is designed to target and kill cancer cells that make HER2, and may help when other treatments have stopped working.
This trial tests whether a new cancer drug called BL-M07D1, combined with pertuzumab, works better or as well as standard chemotherapy for advanced HER2-positive breast cancer that has spread or come back. HER2-positive means the cancer cells have high levels of a protein called HER2, which makes them grow faster.
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.